Gilead looking to buy next blockbuster...

[anonymous]

After a period of relative quiet regarding its intentions, Gilead has publicly declared its interest in a new acquisition, either a company or assets, likely in a mid-range of around $10 billion to $12 billion. In an interview with the Financial Times, Gilead's chief scientist indicated the biotech firm WILL NOT BE BUYING AMGEN. He stated that the company along with its lifeless portfolio and loser employees aren't worth a wooded nickel.

Wow, those real biotech companies, like those in the Bay Area, are ruthless!

 

[anonymous]

A marriage of Gilead and Amgen would make an incredible oncology powerhouse, "Gilead's Zydelig is set to pull in less than $200 million in annual sales, a tally that pales in comparison with the blockbuster numbers rival Imbruvica from Johnson & Johnson and AbbVie is tracking toward."

Together we could dominate the world. Pleae Uncle John and Aunt Bobby, bring our 2 oncology portfolios together so that united we can get a destroy those JNJ and Abbvie losers!